Biotech News
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases.
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
KURAKura Oncology2026-09-09 11:00 EST
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPTSarepta Therapeutics2026-07-29 21:00 EST
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-09-04 12:50 EST
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
INVAInnoviva2026-08-11 20:05 EST
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
GSKGSK plc2026-09-13 08:00 EST
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
GSKGSK plc2026-09-01 07:00 EST
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
Stock data
- Close
- 51.06 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States